After reporting stellar data at ASH, Terns is acquired for $6.7bn.
ApexOnco Front Page
Recent articles
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
New first-in-human study initiations feature yet more in vivo Car assets.
The biotech licenses a China-developed anti-B7-H3 ADC.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Armed with $75m the company takes a risky asset into the clinic.
GEN1286 looks dead, though MCLA-129 continues for now.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
